Drug Database
Back to search

France· FR:69545330

EVENITY 105 mg, solution injectable en stylo prérempli

A romosozumab product containing romosozumab, registered in France by UCB PHARMA BELGIQUE. The same ATC class is registered in 15 of our 19 countries.

ATC M05BX06

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedEVENITY 105 mg, solution injectable e…ATCM05BX06REGISTER NO.FR:69545330PACKS LISTED2CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about romosozumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Romosozumab is registered in 15 of 19 countries.

Countries holding a registration under ATC M05BX06 (romosozumab), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 10 of them publish a price we can compare per daily dose
Search romosozumab products by name

Romosozumab · ATC M05BX06

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of romosozumab costs, country by country.

Normalised to the WHO defined daily dose (7 mg), so markets compare like for like.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Romosozumab · price per daily dose (7 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$19.87
  • ES Spain$17.72
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
ROMOSOZUMAB
Manufacturer
UCB PHARMA BELGIQUE
Country
France (FR)
ATC code
M05BX06
ATC class
Romosozumab
Defined daily dose
7 mg, P
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 2

  • cip13
    3400930204429
    2 seringue(s) préremplie(s) en verre de 1,17 ml dans stylo pré-rempli
  • cip13
    3400955072430
    6 (3 x 2) seringues préremplies en verre de 1,17 ml dans stylo pré-rempli (conditionnement multiple)

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

53 interactions on record for romosozumab.

Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check romosozumab against other medicinesHow interaction checks work

Romosozumab · interactions on record

53 records

  • 1 severe
  • 52 moderate

Most severe, free to view

  • EtelcalcetideH05BX04severe
  • PrednisoloneA07EA01moderate
  • HydrocortisoneA07EA02moderate
  • PrednisoneA07EA03moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Romosozumab in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All romosozumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Evenity
  • Liechtenstein · Evenity
  • Norway · Evenity

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/759b5001-186f-4709-962b-b7a8025029bb
GET /v1/drugs/759b5001-186f-4709-962b-b7a8025029bb?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "69545330",
  "date_amm": "2019-12-09",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/19/1411",
  "substance": "ROMOSOZUMAB",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution injectable",
  "voies_administration": "sous-cutanée",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}
API referenceMCP serverPlans

See everything about romosozumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console